Cargando…
Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care
Purpose: Biomarker data are critical to the delivery of precision cancer care. The average turnaround of next-generation sequencing (NGS) reports is over 2 weeks, and in-house availability is typically limited to academic centers. Lengthy turnaround times for biomarkers can adversely affect outcomes...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947443/ https://www.ncbi.nlm.nih.gov/pubmed/35323313 http://dx.doi.org/10.3390/curroncol29030113 |
_version_ | 1784674440428126208 |
---|---|
author | Sheffield, Brandon S. Beharry, Andrea Diep, Joanne Perdrizet, Kirstin Iafolla, Marco A. J. Raskin, William Dudani, Shaan Brett, Mary Anne Starova, Blerta Olsen, Brian Cheema, Parneet K. |
author_facet | Sheffield, Brandon S. Beharry, Andrea Diep, Joanne Perdrizet, Kirstin Iafolla, Marco A. J. Raskin, William Dudani, Shaan Brett, Mary Anne Starova, Blerta Olsen, Brian Cheema, Parneet K. |
author_sort | Sheffield, Brandon S. |
collection | PubMed |
description | Purpose: Biomarker data are critical to the delivery of precision cancer care. The average turnaround of next-generation sequencing (NGS) reports is over 2 weeks, and in-house availability is typically limited to academic centers. Lengthy turnaround times for biomarkers can adversely affect outcomes. Traditional workflows involve moving specimens through multiple facilities. This study evaluates the feasibility of rapid comprehensive NGS using the Genexus integrated sequencer and a novel streamlined workflow in a community setting. Methods: A retrospective chart review was performed to assess the early experience and performance characteristics of a novel approach to biomarker testing at a large community center. This approach to NGS included an automated workflow utilizing the Genexus integrated sequencer, validated for clinical use. NGS testing was further integrated within a routine immunohistochemistry (IHC) service, utilizing histotechnologists to perform technical aspects of NGS, with results reported directly by anatomic pathologists. Results: Between October 2020 and October 2021, 578 solid tumor samples underwent genomic profiling. Median turnaround time for biomarker results was 3 business days (IQR: 2–5). Four hundred eighty-one (83%) of the cases were resulted in fewer than 5 business days, and 66 (11%) of the cases were resulted simultaneously with diagnosis. Tumor types included lung cancer (310), melanoma (97), and colorectal carcinoma (68), among others. NGS testing detected key driver alterations at expected prevalence rates: lung EGFR (16%), ALK (3%), RET (1%), melanoma BRAF (43%), colorectal RAS/RAF (67%), among others. Conclusion: This is the first study demonstrating clinical implementation of rapid NGS. This supports the feasibility of automated comprehensive NGS performed and interpreted in parallel with diagnostic histopathology and immunohistochemistry. This novel approach to biomarker testing offers considerable advantages to clinical cancer care. |
format | Online Article Text |
id | pubmed-8947443 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89474432022-03-25 Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care Sheffield, Brandon S. Beharry, Andrea Diep, Joanne Perdrizet, Kirstin Iafolla, Marco A. J. Raskin, William Dudani, Shaan Brett, Mary Anne Starova, Blerta Olsen, Brian Cheema, Parneet K. Curr Oncol Article Purpose: Biomarker data are critical to the delivery of precision cancer care. The average turnaround of next-generation sequencing (NGS) reports is over 2 weeks, and in-house availability is typically limited to academic centers. Lengthy turnaround times for biomarkers can adversely affect outcomes. Traditional workflows involve moving specimens through multiple facilities. This study evaluates the feasibility of rapid comprehensive NGS using the Genexus integrated sequencer and a novel streamlined workflow in a community setting. Methods: A retrospective chart review was performed to assess the early experience and performance characteristics of a novel approach to biomarker testing at a large community center. This approach to NGS included an automated workflow utilizing the Genexus integrated sequencer, validated for clinical use. NGS testing was further integrated within a routine immunohistochemistry (IHC) service, utilizing histotechnologists to perform technical aspects of NGS, with results reported directly by anatomic pathologists. Results: Between October 2020 and October 2021, 578 solid tumor samples underwent genomic profiling. Median turnaround time for biomarker results was 3 business days (IQR: 2–5). Four hundred eighty-one (83%) of the cases were resulted in fewer than 5 business days, and 66 (11%) of the cases were resulted simultaneously with diagnosis. Tumor types included lung cancer (310), melanoma (97), and colorectal carcinoma (68), among others. NGS testing detected key driver alterations at expected prevalence rates: lung EGFR (16%), ALK (3%), RET (1%), melanoma BRAF (43%), colorectal RAS/RAF (67%), among others. Conclusion: This is the first study demonstrating clinical implementation of rapid NGS. This supports the feasibility of automated comprehensive NGS performed and interpreted in parallel with diagnostic histopathology and immunohistochemistry. This novel approach to biomarker testing offers considerable advantages to clinical cancer care. MDPI 2022-02-23 /pmc/articles/PMC8947443/ /pubmed/35323313 http://dx.doi.org/10.3390/curroncol29030113 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sheffield, Brandon S. Beharry, Andrea Diep, Joanne Perdrizet, Kirstin Iafolla, Marco A. J. Raskin, William Dudani, Shaan Brett, Mary Anne Starova, Blerta Olsen, Brian Cheema, Parneet K. Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care |
title | Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care |
title_full | Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care |
title_fullStr | Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care |
title_full_unstemmed | Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care |
title_short | Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care |
title_sort | point of care molecular testing: community-based rapid next-generation sequencing to support cancer care |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947443/ https://www.ncbi.nlm.nih.gov/pubmed/35323313 http://dx.doi.org/10.3390/curroncol29030113 |
work_keys_str_mv | AT sheffieldbrandons pointofcaremoleculartestingcommunitybasedrapidnextgenerationsequencingtosupportcancercare AT beharryandrea pointofcaremoleculartestingcommunitybasedrapidnextgenerationsequencingtosupportcancercare AT diepjoanne pointofcaremoleculartestingcommunitybasedrapidnextgenerationsequencingtosupportcancercare AT perdrizetkirstin pointofcaremoleculartestingcommunitybasedrapidnextgenerationsequencingtosupportcancercare AT iafollamarcoaj pointofcaremoleculartestingcommunitybasedrapidnextgenerationsequencingtosupportcancercare AT raskinwilliam pointofcaremoleculartestingcommunitybasedrapidnextgenerationsequencingtosupportcancercare AT dudanishaan pointofcaremoleculartestingcommunitybasedrapidnextgenerationsequencingtosupportcancercare AT brettmaryanne pointofcaremoleculartestingcommunitybasedrapidnextgenerationsequencingtosupportcancercare AT starovablerta pointofcaremoleculartestingcommunitybasedrapidnextgenerationsequencingtosupportcancercare AT olsenbrian pointofcaremoleculartestingcommunitybasedrapidnextgenerationsequencingtosupportcancercare AT cheemaparneetk pointofcaremoleculartestingcommunitybasedrapidnextgenerationsequencingtosupportcancercare |